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26 Oral PresentationsSCT, respectively. A trend for more severe aGVHD and extensive
cGVHD was observed in patients who received peripheral blood
SC from MSD. One year-treatment-related mortality is still low
(7%) in both groups and reflects the high performance quality of
the participating centers. We conclude that allogeneic SCT from
matched donors identified by high resolution typing provides an ex-
cellent chance to rescue children and adolescents with high risk
ALL. The combination of CSA, short MTX and ATG prevents
acute and chronic GVHD without jeopardising the GVL effect.63
OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN 159 YOUNG PATIENTS WITH PEROXISOMAL AND LYSOSOMAL
STORAGE DISORDERS AT A SINGLE CENTER
Prasad, V.K.1, Mendizabal, A.2, Parikh, S.H.1, Szabolcs, P.1,
Driscoll, T.1, Page, K.1, Lakshinarayanan, S.1, Allison, J.1, Wood, S.1,
Semmel, D.1, Escolar, M.L.3, Martin, P.L.1, Carter, S.2,
Kurtzberg, J.1. 1 Duke University Medical Center, Durham, NC; 2 The
EMMES Corporation, Rockville, MD; 3 University of North Carolina,
Chapel Hill, NC.
Background: Bone marrow transplantation benefits patients
with lysosomal and peroxisomal storage diseases (LSD). Umbilical
cord blood (UCB) may be potential graft source for many patients
lacking suitable adult donors. We present the outcomes of Unre-
latedUCB transplantation (UCBT) in a large series of LSDpatients
from a single center. Methods: Using myeloablative conditioning
with busulfan1cyclophosphamide1antithymocyte globulin and
graft-versus-host disease (GvHD) prophylaxis with Cyclospori-
ne1methylprednisolone(n 5 125) or cyclosporine1cellcept (n 5
34), 159 consecutive LSD patients with Hurler, Krabbe, Sanfilippo,
Metachromatic Leukodystrophy, Adrenoleukodystrophy, Hunter,
and other diagnoses received UCBT at Duke in 1995–2007. CBU
from 8 US public banks were screened and those with high-normal
enzyme utilized. Organ function and disease specific studies were
performed pre- and post-UCBT. KM estimates of engraftment,
survival and GvHD probabilities were calculated and multivariate
models were analyzed for a variety of graft and patient factors.
Results: Sixty-two (39%) were girls; 16.3% minorities; 19.5%
CMV seropositive, and 41.5% had a Lansky\ 80%. Age was 1.5
yrs(range 0.05–26.3). Majority of grafts were 5/6(47%) or 4/
6(46%) by intermediate-res HLA-A and -B and high-res HLA-
DRB1. The median(range) cell dose/kg of TNC(pre-cryo),
TNC(infused), CD34(infused) and CFU(post-thaw) was 9.7 
107(2.2–50.4), 7.6  107(1.5–32.4), 2.1  105(0.4–104.8) and 5.7
 104(0.0–105.3), respectively. The cumulative incidence neutro-
phil and platelet engraftment was 87.1% (95%CI 82%-92%) and
71.0% (95%CI 64%-78%) in a median of 22 and 87 days, respec-
tively. The probability of Grade III/IV acute GvHD was
10.3%(95%CI 5%-15%) by day100. Chronic GvHD developed
in 26(13–limited). Overall Survival(OS) at 1, 3, and 5 years was
71.8%(95%CI 65%-79%), 62.7%(95%CI 55%-71%) and
58.2%(95%CI 50%-67%), respectively. In multivariate analysis,
Lansky 80–100(p \ 0.0001), CFU infused .5.7  104/kg (p 5
0.02), and matched ethnicity(p 5 0.05) increased OS. Once en-
grafted, all but 3 maintained chimerism.90% and all but 4 normal-
ized enzymes. In high performance status(Lansky 80–100) patients,
theOS at 1, 3 and 5 yearswas 88.4%, 83.5%, and 79.5%, respectively.
Conclusions: Unrelated Cord blood is an excellent graft source
for treatment of LSD patients, particularly when transplantation is
performed in early stages. Pre-transplant performance status and
post-thaw CFU dosing were highly predictive of overall survival.64
LUNG BIOPSY (BX) HAS A SIGNIFICANTLY HIGHER DIAGNOSTIC YIELD
COMPARED TO BRONCHOALVEOLAR LAVAGE (BAL) IN PEDIATRIC HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS
Cooney-Qualter, E., Satwani, P., van de Ven, C., Baldinger, L., Bye, M.,
Bhatia, M., Garvin, J., George, D., Bradley, M.B., Schwartz, J.,
Wolownik, K., Foley, S., Hawks, R., Kohl, V., Cairo, M.S. Morgan Stan-ley Children’s Hospital of NewYork-Presbyterian, Columbia University,
New York, NY.
Pulmonary complications (PC) following HSCT remain a signif-
icant source of morbidity and mortality in both the early and late
HSCT period. BAL has been a useful initial diagnostic tool in the
evaluation of post HSCT PC; however, the sensitivity of BAL ver-
sus Lung Bx in pediatric HSCT pts has not been analyzed. We re-
viewed 208 pediatric HSCT recipients who underwent a total of
252 HSCT. Allo (174) Myeloablative Conditioning (MAC)
(54%), Reduced Intensity Conditioning (RIC) (45%)and Auto
(78) All MAC. Sixty-six patients (32%) underwent 107 BAL for fe-
ver, respiratory distress, and/or pulmonary infiltrate(s) on chest X-
ray/CT scan: M:F 5 38:28, median age 10 yrs (.33–21), mean # of
BAL/pt 2 (1–8). The probability of requiring BAL after HSCT in
all pts was 23.7% (CI95:18–29.4); RIC 21% (11.5–30.6) vs MAC
24% (16.8–31.6) p 5 0.61 (NS). The median day s/p Auto and
Allo at the time of BAL was Day 131 and 194, respectively. The
probability of AGVHD Grade II-IV at the time of BAL after Allo
SCT was 70% (50–90) and cGVHD was 85% (57–100). The risk
of having cGVHD was significantly higher in the BAL vs no BAL
group (p\0.001). Pathogenswere identified in 37 BAL (35%): Bac-
teria (16), Fungus (12), Viral (13). Seventeen of the 208 pts (8%) un-
derwent a total of 21 lung biopsies. Nineteen (90%) of the biopsies
identified at least one etiology: Infection (12), Fibrosis (4), GVHD
(5), recurrent malignant disease (1). Of the 9 biopsies that were per-
formed within 30 days of an inconclusive BAL (median 13 days s/p
BAL), 6 (67%) identified at least one infection pathogen: Aspergil-
lus (1), CMV (1), Parainfluenza/Influenza (1), Parainfluenza 3 (1),
MAC (1), HSV-1 (1). There were no Grade III/IV toxicity second-
ary to BAL or Bx. Lung autopsies were performed in thirteen pts
(20%) whom underwent a negative BAL. Five (38%) provided at
least one pathogen previously unidentified via BAL performed
within 30 days: Staph Epi (1), Adenovirus (2), CMV (2), Candida
Glabrata (1). The overall survival (OS) in pts whom required BAL
and lung Bx was 45% (16–75) vs 76% (69–83%, p\ 0.003) in the
no BAL and no Bx group This data suggest that a BAL post
HSCT in pediatric recipients will likely only yield a Diagnosis
(Dx) 35% of the time compared to lung Bx which had a 90% diag-
nostic yield. In the future a paradigm will be required to determine
which pediatric HSCT recipients may benefit by having an initial
lung Bx and foregoing an initial BAL to Dx PC.65
INCIDENCE, PREDISPOSING FACTORS AND OUTCOME OF ENGRAFT-
MENT SYNDROME IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT
RECIPIENTS
Albert, M.H.1, Stachel, D.2, Schmid, I.1. 1 Dr. von Haunersches Kinder-
spital der LMU, Munich, Germany; 2 Kinderklinik der Universita¨t Er-
langen, Munich, Germany.
Background: Engraftment syndrome (ES) has been recognized
as an inflammatory condition during neutrophil recovery after he-
matopoietic stem cell transplantation (HSCT) characterized by
non-infectious fever and skin rash. It has been reported to occur fre-
quently after autologous HSCT in children and adults and has been
shown to be an independent risk factor for increased transplant re-
lated mortality. However virtually no data exist on its occurrence
after allogeneic HSCT in children. Methods: To determine inci-
dence, predisposing factors for and complications of ES in a pediat-
ric transplant cohort, we analyzed 61 consecutive recipients of
a myeloablative allogeneic HSCT for the occurrence of ES. Diag-
nosis of ES was established when children presented with $2 of
the following symptoms within 7 days before engraftment: (1) fever
of unknown origin.38.0C, (2) erythematous skin rash, (3) weight
gain $5% and albumin drop # 90% of pretransplant levels or (4)
dyspnea, hypoxia or pulmonary infiltrates. Results: Incidence of
ES in this cohort was 48% (29/61). Post transplant G-CSF admin-
istration (p5 0.03) and a higher number of total nucleated cells (p5
0.02) were significant risk factors predisposing for the development
of ES. Other previously reported factors such as source of stem cells
(BM vs. PB; p5 0.88), underlying disease (malignant vs. non malig-
nant; p 5 0.18), early neutrophil recovery (p 5 0.16) and
Oral Presentations 27amphotericin B therapy (p5 0.08) were not statistically significant.
There was a slight trend towards a higher rate of chronic GVHD in
patients with ES (p 5 0.11). However, after a median follow up of
9.5 years overall survival (48% with ES vs. 50% without ES; p 5
0.53) and transplant related mortality (21% vs. 17%; p 5 0.65)
did not differ between the two groups. Prednisolone (2 mg/kg/d)
was administered in 62% of children with ES.Conclusion: ES pre-
senting with fever, rash, weight gain and pulmonary symptoms
should be recognized as a frequent complication of allogeneic
HSCT after myeloablative conditioning in children. Treatment
withG-CSF and a high nucleated cell count of the graft predisposed
for the development of ES in this study. Overall survival and trans-
plant relatedmortality in this cohort were not affected by the occur-
rence of ES, possibly due to therapeutic intervention with
prednisolone in a high proportion of patients.66
EXCELLENT ENGRAFTMENT AND RAPID IMMUNE RECOVERY IN HAP-
LOIDENTICAL STEM CELL TRANSPLANTATION USING CD3/CD19 DE-
PLETED PERIPHERAL STEM CELL GRAFTS AFTER REDUCED
INTENSITY CONDITIONING
Bader, P.1, Soerensen, J.1, Koehl, U.1, Kreyenberg, H.1, Jarisch, A.1,
Weber, G.1, Sach, G.1, Willasch, A.1, Kuci, S.1, Tonn, T.2, Esser, R.1,
Klingebiel, T.1. 1 JW Goethe University Children’s Hospital, Frankfurt,
Germany; 2 Institut fu¨r Transfusionsmedizin, Frankfurt, Germany.
Transplantation of haploidentical stem cells has become a well
established treatment procedure in many children with malignant
and non malignant diseases. Positive enrichment of stem cells by
anti-CD34 magnetic micro beads provides a graft profoundly de-
pleted of T and B cells facilitating engraftment without inducing se-
vere GVHD. However, despite transplanting ‘‘mega doses’’ (.107/
kgBW) of stem cells, primary graft rejection and delayed immune
recovery associated with increased transplant related mortality re-
mained major obstacles. Grafts after depletion of CD3/CD19 cells
consist of remarkable amounts of effector cells which might help to
improve engraftment and immune reconstitution.
We report the results of our pilot study including 29 children and
adolescents (ALL, n5 10; AML, n5 3; RMA, n5 10; aplastic anae-
mia, n5 1, MDS, n5 2 and NBL/HB n5 2). All patients received
CD3/CD19 depleted peripheral stem cell grafts containing a me-
dian number of 7.46/kgBW CD341 cells. Grafts also contained
NK-cells (median number: 14.36/kgBW), dendritic cells, precursor
T-cells and mono-/granulocytes (median number: 423.46/kgBW).
All patients but two received a reduced conditioning regimen with
FLU-MEL-THIO and short course of OKT-3. All twenty-nine pa-
tients achieved rapid engraftment at day 14 and 156 days, respec-
tively. Immune recovery was excellent with a median time to
achieve more than 100 CD31 and CD41 cells/ml was 61.0 and
63.5 days, respectively. Five/29 patients developed acute GvHD
grade II and grade III (n 5 2). Fourteen out of 29 patients (48%)
are alive and in CR with a median follow-up of 282 days (range:
42–968 days). Two heavily pre-treated patients died due to TRM.
Ten patients died due to relapse of their underlying disease. Two
patients died of Adeno virus infection. In conclusion, haploidentical
transplantation using CD3/CD19 depleted grafts seems to be a fea-
sible strategy to overcome the high risk of graft rejection and to im-
prove immune reconstitution.67
CLINICAL OUTCOMES OF ADOLESCENT PATIENTS UNDERGOING HEMA-
TOPOIETIC STEM CELL TRANSPLANT
Midura, B.2, Lehmann, L.1, Duncan, C.1. 1 Dana-Farber Cancer Insti-
tue, Boston, MA; 2 Children’s Hospital, Boston, Boston, MA.
There is concern that the outcome for adolescent oncology pa-
tients is worse than that of younger patients with the same disease.
The effect of patient age on outcome following pediatric allogeneic
hematopoietic stem cell transplant (HSCT) has not been well de-
scribed. We retrospectively reviewed the medical records of all pe-diatric allogeneicHSCTpatients at our institution between January
1, 2001 and December 31, 2006. We investigated survival, cause of
death, and occurrence of graft-versus-host disease (GVHD) in pa-
tients 15–21 years old at time of HSCT compared with patients
10–14.9 years old at transplant. 127 patients greater than 10 years
old (10–14.9 years 5 73 patients; greater than 15 years 5 54 pa-
tients) were transplanted during the study period. Indications for
HSCT were similar in both groups (see table). 53.4% of patients
in the younger group received unrelated donor (URD) transplants
compared with 48.1% in the older group. A greater percentage of
patients in the younger group received cells from a donor matched
at less than 6 HLA loci (20.5% versus 9.3%). There was no statisti-
cally significant difference in the incidence of chronic GVHD
(younger 42.5%, older 46.2%). Patients greater than 15 years old
had a higher risk of mortality compared to younger patients (odds
ratio5 1.85). Relapse was the cause of death (COD) in 13.7%of pa-
tients in the younger group and 16.7% of patients in the older
group. Transplant related mortality (TRM) was greater in the older
group (younger 16.4%, older 27.8%). Older adolescents had in-
creased toxicity resulting in increased mortality following HSCT
compared to younger adolescents with similar underlying disease
and transplant characteristics. Further study is needed to better un-
derstand these findings and their potential impact on the care of ad-
olescent stem cell transplant patients.
Younger Adolescents Compared with Older Adolescents
Age 10–14.9 Age .15
years (n5 73) years (n5 54)Death 22 (30.1%) 24 (44.4%)
Cause of death: Relapse 10 9
Cause of death: TRM 12 15
Chronic GVHD 31 (42.5%) 25 (46.2%)
Related donor 34 (46.6%) 28 (51.9%)
Source: bone marrow 65 (89%) 51 (94.6%)
Acute lymphoblastic 24 (32.9%) 14 (25.9%)
Acute myelogenous leukemia/
myelodysplasia26 (35.6%) 20 (37%)Chronic myelogenous
leukemia8 (11%) 8 (14.8%)Nonmalignant hematologic
disease9 (12.3%) 10 (18.5%)Other 6 (8.2%) 2 (3.7%)68
GENE THERAPY FOR ADENOSINE DEAMINASE (ADA)-DEFICIENT SE-
VERE COMBINED IMMUNE DEFICIENCY (SCID): COMPARATIVE RE-
SULTS WITH OR WITHOUT PEG-ADA WITHDRAWAL AND
MYELOSUPPRESSIVE CHEMOTHERAPY
Podsakoff, G.1, Engel, B.C.1, Sokolic, R.2, Carbonaro, D.A.1, Muul, L.2,
Garabedian, E.2, Ireland, J.1, Hershfield, M.3, Wayne, A.4, Dunbar, C.5,
Candotti, F.2, Kohn, D.B.1. 1 Childrens Hospital Los Angeles, Los Angeles,
CA; 2 National Institutes of Health, Bethesda, MD; 3 Duke University
Medical Center, Durham, NC; 4 National Institutes of Health, Bethesda,
MD; 5 National Institutes of Health, Bethesda, MD.
In 2001–2002, we treated 4 ADA-SCIDpatients in a gene therapy
(GTx) clinical trial evaluating the efficacy of 2 different retroviral
vectors while continuing enzyme replacement with pegylated bo-
vine ADA (PEG-ADA). No cytoreductive conditioning was used.
All patients have been monitored for 6 years. No treatment-related
SAE occurred. A mild transient elevation in absolute lymphocyte
count (ALC) was seen in 2 patients early post-treatment, however,
no durable immunologic changes were observed. Low levels (0.1–
0.7%) of vector-marked PBMC persist for at least five years in 2 pa-
tients treated at the age of 4–5 years. All patients remain on PEG-
ADA, prophylactic antibiotics and IVIg. In 2004, we revised the
protocol to facilitate engraftment and selective advantage of gene-
corrected cells by withdrawing PEG-ADA and giving busulfan
(75 mg/m2) before GTx. In November 2005, a 1st patient was
treated who developed unexpected prolonged bone marrow (BM)
